HuangCWangYLiX, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet.2020;395(10223):497–506.
2.
NaveedMUddinSAbdullahKS, et al.Various evidence-based hypothetical and experimental treatment approaches and their effectiveness against COVID-19 worldwide: a comprehensive literature review. EMJO. 2020;4:265–285.
3.
LuH. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.
4.
KhanZKarataşYRahmanH.Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther. 2020:37(6):2575–2579.
5.
DongLHuSGaoJ. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.
6.
FernerREAronsonJK. Remdesivir in Covid-19. BMJP Group. 2020:369:m1610.
7.
Clinicaltrials.gov. Remdesivir | Covid-19. 2020.
8.
GordonCJTchesnokovEPFengJY, et al.The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–4779.
9.
ElfikyAA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477.
10.
SheahanTPSimsACGrahamRL, et al.Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(393):eaa13653.
11.
HarrisonC. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379–381.
12.
(EMA) EMA. Compassionate Use Opinions. European Medicine Agency; 2020.
13.
WangMCaoRZhangL, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
14.
AgostiniMLAndresELSimsAC, et al.Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.
15.
LiGDe ClercqE. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nature Publishing Group; 2020.
16.
de WitEFeldmannFCroninJ, et al.Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Nat Acad Sci USA.2020;117(12):6771–6776.
17.
HolshueMLDeBoltCLindquistS, et al.First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
18.
GreinJOhmagariNShinD, et al.Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
19.
WangYZhangDDuG, et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10326):1569–1578.
20.
BeigelJHTomashekKMDoddLE. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(10):994.
21.
Steve HollandDB. U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir. US News & World Report. May 2020.
22.
SternlichtA. Japan approves remdesivir for use On Severe COVID-19 Patients. Forbes. May 2020.
23.
RajagopalD. Gilead sign licensing deal for remdesivir with three Indian companies. The Economic Times. May 2020.
